How much funding has Mineralys Therapeutics raised?

Mineralys Therapeutics has raised $428.0M in total funding, most recently a Corporate Round.

Who are Mineralys Therapeutics's investors?

Mineralys Therapeutics's investors include Pharmakon Advisors, RA Capital Management, Andera Partners, HBM Healthcare Investments, Samsara BioCapital, Ysios Capital.

When was Mineralys Therapeutics founded?

Mineralys Therapeutics was founded in 2019.

Where is Mineralys Therapeutics headquartered?

Mineralys Therapeutics is headquartered in Radnor, Pennsylvania, United States.

What industry is Mineralys Therapeutics in?

Mineralys Therapeutics operates in Biotech, Healthcare.

How many employees does Mineralys Therapeutics have?

Mineralys Therapeutics has 11-50 employees.

Mineralys Therapeutics

IPO

Targeting aldosterone to improve outcomes in hypertension and cardiorenal disease

Public · Radnor, United States · Founded 2019 · $428.0M raised

Biotech

Healthcare

Headquarters: Radnor, Pennsylvania
Employees: 11–50
Founded: 2019
Business Model: B2B
Website: mineralystx.com

Total Funding: $428.0M
Last Round: $150.0M Corporate RoundJun 2026
Rounds: 4
Type: Public

About

Mineralys Therapeutics is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Radnor, Pennsylvania, focused on developing medicines that target aldosterone-driven cardiovascular and renal diseases. The company's lead product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being evaluated in Phase 3 trials for the treatment of hypertension and chronic kidney disease (CKD) within the broader cardio-renal-metabolic syndrome. Mineralys was founded by Catalys Pacific and is led by CEO Jon Congleton, a 35-year industry veteran. The company went public on NASDAQ (ticker: MLYS) and has approximately 51 employees.

Summary

Mineralys Therapeutics is a Biotech company based in Radnor, United States, founded in 2019. It has raised $428.0M in total across 4 rounds, most recently a $150.0M Corporate Round round in Jun 2026. Investors include Pharmakon Advisors, RA Capital Management and Andera Partners.

LinkedIn X (Twitter)